XML 49 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)
$ in Millions
3 Months Ended
Jun. 30, 2021
USD ($)
Europe [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Remainder of transaction price, variable consideration from estimated future co-development billing $ 10.7
Europe [Member] | Astellas Agreement [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue from changes to estimated variable consideration 0.4
U.S./RoW and China [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Remainder of transaction price, variable consideration from estimated future co-development billing 34.1
U.S./RoW and China [Member] | AstraZeneca Agreements [Member]  
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]  
Changes in revenue from changes to estimated variable consideration $ 0.2